Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer

被引:50
作者
Dey, Amit [1 ]
Mitra, Abhijit [1 ]
Pathak, Surajit [1 ]
Prasad, Suhanya [2 ]
Zhang, Alexander Sun [3 ]
Zhang, Hong [4 ]
Sun, Xiao-Feng [5 ,6 ,7 ,8 ]
Banerjee, Antara [1 ,9 ]
机构
[1] Chettinad Hosp & Res Inst, Fac Allied Hlth Sci, Chettinad Acad Res & Educ, Chennai, India
[2] Med Univ Bialystok, Dept Med Microbiol & Nanobiomed Engn, Bialystok, Poland
[3] Karolinska Inst, Dept Oncol Pathol, Solna, Sweden
[4] Orebro Univ, Sch Med, Dept Med Sci, Orebro, Sweden
[5] Linkoping Univ, Dept Oncol, Linkoping, Sweden
[6] Linkoping Univ, Dept Biomed & Clin Sci, Linkoping, Sweden
[7] Linkoping Univ, Dept Oncol, S-58183 Linkoping, Sweden
[8] Linkoping Univ, Dept Biomed & Clin Sci, S-58183 Linkoping, Sweden
[9] Chettinad Hosp & Res Inst, Chettinad Acad Res & Educ, Fac Allied Hlth Sci, Dept Med Biotechnol, Chennai 603103, Tamil Nadu, India
关键词
colon cancer; personalized treatment; precision medicine; targeted therapy; immunotherapy; METASTATIC COLORECTAL-CANCER; COMPLETE MESOCOLIC EXCISION; DNA MISMATCH REPAIR; PRECISION MEDICINE; COMBINED BRAF; T-CELL; INHIBITION; EXPRESSION; MUTATIONS; ENCORAFENIB;
D O I
10.1177/15330338231178403
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile and biomarkers associated with the process are considered in personalized medicine, along with the patient's personal history. It is based on the response of the targeted therapies to specific genetic variations. The patient's genetic transcriptomic and epigenetic features are evaluated, and the best therapeutic approach and diagnostic testing are identified through personalized medicine. This review aims to summarize all the necessary, updated information on colon cancer related to personalized medicine. Personalized medicine is gaining prominence as generalized treatments are finding it challenging to contain colon cancer cases which currently rank fourth among global cancer incidence while being the fifth largest in total death cases worldwide. In personalized therapy, patients are grouped into specific categories, and the best therapeutic approach is chosen based on evaluating their molecular features. Various personalized strategies are currently being explored in the treatment of colon cancer involving immunotherapy, phytochemicals, and other biomarker-specific targeted therapies. However, significant challenges must be overcome to integrate personalized medicine into healthcare systems completely. We look at the various signaling pathways and genetic and epigenetic alterations associated with colon cancer to understand and identify biomarkers useful in targeted therapy. The current personalized therapies available in colon cancer treatment and the strategies being explored to improve the existing methods are discussed. This review highlights the advantages and limitations of personalized medicine in colon cancer therapy. The current scenario of personalized medicine in developed countries and the challenges faced in middle- and low-income countries are also summarized. Finally, we discuss the future perspectives of personalized medicine in colon cancer and how it could be integrated into the healthcare systems.
引用
收藏
页数:21
相关论文
共 195 条
[1]   Antigenotoxic effects of resveratrol: assessment of in vitro and in vivo response [J].
Abraham, Suresh K. ;
Khandelwal, Nidhi ;
Hintzsche, Henning ;
Stopper, Helga .
MUTAGENESIS, 2016, 31 (01) :27-33
[2]   Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve Status Quo [J].
Adeniji, Adeoluwa Akeem ;
Dulal, Soniya ;
Martin, Mike G. .
WORLD JOURNAL OF ONCOLOGY, 2021, 12 (2-3) :50-60
[3]   Colon Cancer: A Clinician's Perspective in 2019 [J].
Ahmed, Monjur .
GASTROENTEROLOGY RESEARCH, 2020, 13 (01) :1-10
[4]   Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation [J].
Al-Salama, Zaina T. .
DRUGS, 2021, 81 (07) :849-856
[5]  
Alcindor T, 2011, CURR ONCOL, V18, P18
[6]   Inhibition of the Wnt/b-catenin pathway using PNU-74654 reduces tumor growth in in vitro and in vivo models of colorectal cancer [J].
Amerizadeh, Forouzan ;
Rahmani, Farzad ;
Maftooh, Mina ;
Nasiri, Seyedeh-Najibeh ;
Hassanian, Seyed Mahdi ;
Giovannetti, Elisa ;
Moradi-Marjaneh, Reyhaneh ;
Sabbaghzadeh, Reihaneh ;
Shahidsales, Soodabeh ;
Joudi-Mashhad, Mona ;
Ghayour-Mobarhan, Majid ;
Ferns, Gordon A. ;
Khazaei, Majid ;
Avan, Amir .
TISSUE & CELL, 2022, 77
[7]   Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].
Andre, T. ;
Shiu, K-K ;
Kim, T. W. ;
Jensen, B., V ;
Jensen, L. H. ;
Punt, C. ;
Smith, D. ;
Garcia-Carbonero, R. ;
Benavides, M. ;
Gibbs, P. ;
de la Fouchardiere, C. ;
Rivera, F. ;
Elez, E. ;
Bendell, J. ;
Le, D. T. ;
Yoshino, T. ;
Van Cutsem, E. ;
Yang, P. ;
Farooqui, M. Z. H. ;
Marinello, P. ;
Diaz, L. A., Jr. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218
[8]  
Andre Thierry, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_349557
[9]   Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments [J].
不详 .
ONCOTARGETS AND THERAPY, 2022, 15 :747-756
[10]  
[Anonymous], 2012, HOC INADEQUATE THAIL, P1